Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
- 1 July 2020
- journal article
- letter
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (7) , e124-e127
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyThe Lancet Oncology, 2020
- MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerClinical Cancer Research, 2020
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesJournal of Thoracic Oncology, 2020
- Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinomaInternational Journal of Cancer, 2018
- Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialThe Lancet Oncology, 2016